Provided by Tiger Fintech (Singapore) Pte. Ltd.

Trevi Therapeutics, Inc.

6.91
+0.60009.51%
Post-market: 6.910.00000.00%19:27 EDT
Volume:1.58M
Turnover:10.59M
Market Cap:668.07M
PE:-14.71
High:7.02
Open:6.25
Low:6.14
Close:6.31
Loading ...

Analysts Have Conflicting Sentiments on These Healthcare Companies: BioNTech SE (BNTX) and Trevi Therapeutics (TRVI)

TIPRANKS
·
11 Mar

HC Wainwright Adjusts Trevi Therapeutics Price Target to $12.50 From $7.50, Maintains Buy Rating

MT Newswires Live
·
11 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Willis Lease Finance, CME Group

Reuters
·
11 Mar

Leerink Adjusts Price Target on Trevi Therapeutics to $11 From $7, Maintains Outperform Rating

MT Newswires Live
·
10 Mar

Trevi Therapeutics Reveals Positive Data From Mid-Stage Study For Chronic Cough Candidate, Stock Jumps

Benzinga
·
10 Mar

Trevi Therapeutics Inc : Leerink Partners Raises Target Price to $11 From $7

THOMSON REUTERS
·
10 Mar

Trevi Shares Climb On Positive Results for Chronic Cough Treatment

Dow Jones
·
10 Mar

Trevi Therapeutics Shares Jump Over 60% After Cough Therapy Succeeds in Mid-Stage Trial

THOMSON REUTERS
·
10 Mar

Analysts’ Top Healthcare Picks: Trevi Therapeutics (TRVI), Oncolytics Biotech (ONCY)

TIPRANKS
·
10 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Primo Brands, Cracker Barrel, Redfin

Reuters
·
10 Mar

Recession Fears Drive Premarket Losses for US Equity

MT Newswires Live
·
10 Mar

Top Premarket Gainers

MT Newswires Live
·
10 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Airbnb, Beacon, Redfin

Reuters
·
10 Mar

Trevi Therapeutics Says Phase 2a Haduvio Trial Shows Significant Reduction in Cough Count

MT Newswires Live
·
10 Mar

Trevi Therapeutics Is Maintained at Buy by Needham

Dow Jones
·
10 Mar

Trevi Therapeutics Inc : Needham Raises Target Price to $25 From $8

THOMSON REUTERS
·
10 Mar

BUZZ-Trevi jumps as chronic cough therapy succeeds mid-stage trial

Reuters
·
10 Mar

Trevi Therapeutics Shares up 21.6% Premarket as Cough Therapy Succeeds in Mid-Stage Trial

THOMSON REUTERS
·
10 Mar

BRIEF-Trevi Therapeutics Announces Positive Topline Results From Its Phase 2a RIVER Trial Of Haduvio For Treatment Of Patients With RCC

Reuters
·
10 Mar

Trevi Therapeutics: Patient Reported & Other Secondary Outcomes Were Statistically Significant & Consistent With Primary Endpoint

THOMSON REUTERS
·
10 Mar